Stockscreener 앱 받기
7.59
2.71%
0.20
시간 외 거래:
7.63
0.04
+0.53%
전일 마감가:
$7.39
열려 있는:
$7.38
하루 거래량:
400.93K
Relative Volume:
1.23
시가총액:
$667.99M
수익:
-
순이익/손실:
$-42.63M
주가수익비율:
-14.37
EPS:
-0.5281
순현금흐름:
$-39.43M
1주 성능:
+2.99%
1개월 성능:
+11.13%
6개월 성능:
+99.53%
1년 성능:
+193.05%
1일 변동 폭
$7.30
$7.70
1주일 범위
$7.1701
$9.071
52주 변동 폭
$2.57
$9.071
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
7.59 | 650.39M | 0 | -42.63M | -39.43M | -0.5281 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-04-24 | 개시 | H.C. Wainwright | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 개시 | Piper Sandler | Overweight |
| 2022-04-04 | 개시 | Citigroup | Buy |
모두보기
Alpha Tau Medical Ltd 주식(DRTS)의 최신 뉴스
Alpha Tau to Present Alpha DaRT–Pembrolizumab Head and Neck Cancer Data at AHNS 2026 - TipRanks
Alpha Tau abstract on cancer therapy accepted for presentation By Investing.com - Investing.com Canada
Elderly head and neck cancer study gets AHNS podium slot - Stock Titan
Alpha Tau (DRTS) wins AHNS podium slot for Alpha DaRT and pembrolizumab head and neck cancer study - Stock Titan
Alpha Tau pancreatic data: 19 of 19 controlled, 8 device events - Stock Titan
Alpha Tau reports disease control in pancreatic cancer trial By Investing.com - Investing.com Australia
Alpha Tau reports disease control in pancreatic cancer trial - Investing.com
Alpha Tau Reports 100% Local Disease Control in Alpha DaRT Pancreatic Cancer Trials Presented at DDW 2026 - TipRanks
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 - The Manila Times
Alpha Tau Announces 100% Local Disease Control Rate and - GlobeNewswire
[EFFECT] Alpha Tau Medical Ltd. SEC Filing - Stock Titan
Alpha Tau Medical (NASDAQ:DRTS) Reaches New 1-Year HighTime to Buy? - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Trading Up 13.6%Here's What Happened - MarketBeat
Alpha Tau Medical (NASDAQ: DRTS) files $300M shelf; $100M ATM pact - Stock Titan
Alpha Tau to Present Pooled Pancreatic Cancer Alpha DaRT Data at 2026 ASCO Meeting - TipRanks
Alpha Tau abstract accepted at ASCO annual meeting in May - Investing.com
Alpha Tau abstract accepted at ASCO annual meeting in May By Investing.com - Investing.com Canada
Alpha Tau Announces Presentation of Pancreatic Cancer Data - GlobeNewswire
Alpha Tau (Nasdaq: DRTS) ASCO abstract pools 58 pancreatic cancer patients - Stock Titan
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA approval - Investing.com
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA approval By Investing.com - Investing.com South Africa
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Alpha Tau Wins FDA Clearance To Expand Alpha DaRT Pancreatic Cancer Trial - RTTNews
Alpha Tau Treats First European Pancreatic Cancer Patient With Alpha DaRT in ACAPELLA Trial - TipRanks
Alpha Tau (NASDAQ: DRTS) advances Alpha DaRT pancreatic cancer clinical trials - Stock Titan
Alpha Tau Announces FDA Approval of IDE Supplement to - GlobeNewswire
Alpha Tau Successfully Treats First Pancreatic Cancer - GlobeNewswire
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Alpha Tau Medical (DRTS) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
Alpha Tau Medical (DRTS) Investor presentation Summary - Quartr
Alpha Tau Medical (DRTS) 2nd Annual Lytham Partners Healthcare Investor Summit summary - Quartr
Is Alpha Tau (DRTS) stock trading at a discount | Q4 2025: Profit Exceeds ViewsPopular Market Picks - Cổng thông tin điện tử Tỉnh Sơn La
DRTS (Alpha Tau Medical Ltd. Ordinary Shares) posts narrower Q4 2025 loss than estimates, shares rise 0.75 percent today.GDR - Cổng thông tin điện tử tỉnh Lào Cai
S Morry Blumenfeld Net Worth (2026) - GuruFocus
Alan Adler Net Worth (2026) - GuruFocus
Maya Netser Net Worth (2026) - GuruFocus
Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (GEHC), Immunome (IMNM) and Eli Lilly & Co (LLY) - The Globe and Mail
Michael Avruch Net Worth (2026) - GuruFocus
Uzi Sofer Net Worth (2026) - GuruFocus
Raphi Levy Net Worth (2026) - GuruFocus
Alpha Tau Medical Ltd. (DRTS) Stock Analysis: Exploring a 20.56% Potential Upside in Biotechnology - DirectorsTalk Interviews
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
DRTS Options Volatility — NASDAQ:DRTS - TradingView
DRTS Options Chain — NASDAQ:DRTS - TradingView
Shorts Report: Will Alpha Tau Medical Ltd Equity Warrant stock benefit from M A2026 Earnings Surprises & High Return Trade Guides - baoquankhu1.vn
Growth Recap: Will Alpha Tau Medical Ltd Equity Warrant benefit from rising consumer demandQuarterly Trade Review & High Conviction Investment Ideas - baoquankhu1.vn
Jobs Data: Can Alpha Tau Medical Ltd continue delivering strong returnsEarnings Overview Summary & Safe Capital Preservation Plans - baoquankhu1.vn
ETFs Investing in Alpha Tau Medical Ltd Stocks - TradingView
Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS - MarketBeat
FOMO Trade: Will Alpha Tau Medical Ltd Equity Warrant stock benefit from M A2026 Geopolitical Influence & AI Based Trade Execution Alerts - baoquankhu1.vn
Alpha Tau Medical Ltd (DRTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):